Table 1.
Anticancer screening data at the concentration of 10 μM.
| Comp | 60 Cell lines assay in 1 dose 10 μM concentration |
|||
|---|---|---|---|---|
| Mean growth % | Range of growth % | The most sensitive cell lines | Growth % of the most sensitive cell lines | |
| 1a | 101.55 | 77.50–113.87 | UO-31 (Renal Cancer) | 77.50 |
| 1b | 104.84 | 74.89–169.65 | HOP-92 (Non-Small Cell Lung Cancer) | 74.89 |
| 2a | 99.23 | 76.58–113.53 | UO-31 (Renal Cancer) | 76.58 |
| 3a | 100.94 | 69.54 to 112.74 | HOP-92 (Non-Small Cell Lung Cancer) | 69.54 |
| 3b | 99.49 | 67.47–122.33 | OVCAR-4 (Ovarian Cancer) | 67.47 |
| 3c | 100.67 | 82.16–126.20 | UO-31 (Renal Cancer) | 82.16 |
| 3d | 102.96 | 74.48–127.35 | UO-31 (Renal Cancer) | 74.48 |
| 3f | 102.12 | 76.37–131.30 | K-562 (Leukemia) | 76.37 |
| 4a | 96.64 | 39.09–147.38 | SR (Leukemia) | 39.09 |
| K-562 (Leukemia) | 58.20 | |||
| RPMI-8226 (Leukemia) | 58.85 | |||
| LOX IMVI (Melanoma): | 55.70 | |||
| 4d | 60.11 | −27.33–160.47 | CCRF-CEM (Leukemia) | 19.50 |
| HL-60(TB) (Leukemia) | −27.33 | |||
| K-562 (Leukemia) | 33.24 | |||
| MOLT-4 (Leukemia) | 16.47 | |||
| HOP-92 (Non-Small Cell Lung Cancer) | 37.75 | |||
| KM12 (Colon Cancer) | 29.89 | |||
| SF-295 (CNS Cancer) | −13.37 | |||
| OVCAR-3 (Ovarian Cancer) | 36.41 | |||
| RXF 393 (Renal Cancer) | 31.39 | |||
| PC-3 (Prostate Cancer) | 33.62 | |||
| MCF7 (Breast Cancer) | 30.34 | |||
| T-47D (Breast Cancer) | 37.99 | |||
| 4e | 99.73 | 78.68–132.27 | T-47D (Breast Cancer) | 78.68 |
| 4f | 51.05 | −5.27–109.26 | CCRF-CEM (Leukemia) | 16.67 |
| HL-60(TB) (Leukemia) | 13.51 | |||
| K-562 (Leukemia) | 24.64 | |||
| MOLT-4 (Leukemia) | 11.47 | |||
| RPMI-8226 (Leukemia) | 2.48 | |||
| SR (Leukemia) | 10.57 | |||
| NCI-H522 (Non-Small Cell Lung Cancer) | 23.21 | |||
| A549/ATCC (Non-Small Cell Lung Cancer) | 30.04 | |||
| NCI-H460 (Non-Small Cell Lung Cancer) | 25.93 | |||
| KM12 (Colon Cancer) | 25.76 | |||
| SF-295 (CNS Cancer) | −5.27 | |||
| UACC-62 (Melanoma) | 32.77 | |||
| MDA-MB-435 (Melanoma) | 39.46 | |||
| PC-3 (Prostate Cancer) | 35.99 | |||
| MCF7 (Breast Cancer) | 34.41 | |||
| HS 578T (Breast Cancer) | 35.58 | |||
| BT-549 (Breast Cancer) | 34.25 | |||
| T-47D | 39.30 | |||
| 5d | 97.97 | 74.66–118.66 | CCRF-CEM (Leukemia) | 74.66 |